Anti-tumour necrosis factor therapy in seronegative spondyloarthritis

被引：0

作者：

Swales, C ^{[1
]}

Bowness, P ^{[1
]}

机构：

[1] Nuffield Orthopaed Ctr NHS Trust, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England

来源：

CLINICAL MEDICINE | 2005年 / 5卷 / 03期

关键词：

D O I：

10.7861/clinmedicine.5-3-219

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is probably as effective as initial treatment Pre-test screening for tuberculosis is essential The overall risk to benefit ratio is favourable.

引用

页码：219 / 222

页数：4

共 50 条

[1] Anti-tumour necrosis factor therapy in the West Midlands
Bartram, D
Sheeran, T
Price, T
Mulherin, D
RHEUMATOLOGY, 2004, 43 (03) : 400 - 400
[2] Anti-tumour necrosis factor (TNF)-α therapy (etanercept)
Maya Buch
Arthritis Research & Therapy, 4 (1)
[3] SMOKING IMPACT IN THE EFFECTIVENESS OF ANTI-TUMOUR NECROSIS FACTOR-ALPHA THERAPY IN PORTUGUESE SPONDYLOARTHRITIS PATIENTS
Aguiar, F.
Rosa-Goncalves, D.
Fonseca, R.
Vieira, R.
Madureira, P.
Bernardo, A.
Bernardes, M.
Brito, I.
Costa, L.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1146 - 1146
[4] Optic neuritis occurring with anti-tumour necrosis factor α therapy
Simsek, Ismail
Erdem, Hakan
Pay, Salih
Sobaci, Gungor
Dinc, Ayhan
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1255 - 1258
[5] Problems encountered during anti-tumour necrosis factor therapy
Desai, Sheetal B.
Furst, Daniel E.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (04): : 757 - 790
[6] The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
Askling, Johan
Dixon, Will
CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) : 138 - 144
[7] Demyelination during anti-tumour necrosis factor therapy for psoriasis
Boggs, J. M. E.
Barnes, L.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (05) : 577 - 578
[8] Retention on anti-tumour necrosis factor therapy: the Waikato experience
Ip, Ken
Hartley, Lorraine
Solanki, Kamal
White, Douglas
NEW ZEALAND MEDICAL JOURNAL, 2015, 128 (1415) : 34 - 40
[9] Anti-Tumour Necrosis Factor Therapy for Ulcerative ColitisEvidence to Date
Chandrashekhar Thukral
Adam Cheifetz
Mark A. Peppercorn
Drugs, 2006, 66 : 2059 - 2065
[10] Anti-tumour necrosis factor therapy associated with cutaneous vasculitis
Livermore, PA
Murray, KJ
RHEUMATOLOGY, 2002, 41 (12) : 1450 - 1452

← 1 2 3 4 5 →